KR101670299B1 - 안드로겐 수용체 조절 화합물 - Google Patents
안드로겐 수용체 조절 화합물 Download PDFInfo
- Publication number
- KR101670299B1 KR101670299B1 KR1020167023703A KR20167023703A KR101670299B1 KR 101670299 B1 KR101670299 B1 KR 101670299B1 KR 1020167023703 A KR1020167023703 A KR 1020167023703A KR 20167023703 A KR20167023703 A KR 20167023703A KR 101670299 B1 KR101670299 B1 KR 101670299B1
- Authority
- KR
- South Korea
- Prior art keywords
- mmol
- pyrazol
- chloro
- carboxamide
- added
- Prior art date
Links
- 0 CC(*)([C@](*(*)C(C(C)(CCC1)CCC(C)(*)CC1(*)O)=O)C1*)C1(*)*(C=C1)*=C1c1cnccc1 Chemical compound CC(*)([C@](*(*)C(C(C)(CCC1)CCC(C)(*)CC1(*)O)=O)C1*)C1(*)*(C=C1)*=C1c1cnccc1 0.000 description 8
- IDHRHHLXBFGLSE-UHFFFAOYSA-N C1Cc2ccn[n]2CC1 Chemical compound C1Cc2ccn[n]2CC1 IDHRHHLXBFGLSE-UHFFFAOYSA-N 0.000 description 1
- KOPKCRFWMYEQBG-UHFFFAOYSA-N CC(C(CCCC1)=C1ON)=C Chemical compound CC(C(CCCC1)=C1ON)=C KOPKCRFWMYEQBG-UHFFFAOYSA-N 0.000 description 1
- WGVHNCAJPFIFCR-UHFFFAOYSA-N CC(NN1)=CC1=O Chemical compound CC(NN1)=CC1=O WGVHNCAJPFIFCR-UHFFFAOYSA-N 0.000 description 1
- MRAXWGDMQACKAM-UHFFFAOYSA-N Cc1c(COCC2)c2n[nH]1 Chemical compound Cc1c(COCC2)c2n[nH]1 MRAXWGDMQACKAM-UHFFFAOYSA-N 0.000 description 1
- XLSZMDLNRCVEIJ-UHFFFAOYSA-N Cc1c[nH]cn1 Chemical compound Cc1c[nH]cn1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 description 1
- GVSNQMFKEPBIOY-UHFFFAOYSA-N Cc1c[nH]nn1 Chemical compound Cc1c[nH]nn1 GVSNQMFKEPBIOY-UHFFFAOYSA-N 0.000 description 1
- FPOMHKYYXZJGGG-UHFFFAOYSA-N Cc1c[n](C(CCC2)OC3[IH]C[IH]3)c2n1 Chemical compound Cc1c[n](C(CCC2)OC3[IH]C[IH]3)c2n1 FPOMHKYYXZJGGG-UHFFFAOYSA-N 0.000 description 1
- VJISEYLRRDUZHP-UHFFFAOYSA-N Cc1c[n](CCNC2)c2n1 Chemical compound Cc1c[n](CCNC2)c2n1 VJISEYLRRDUZHP-UHFFFAOYSA-N 0.000 description 1
- VFPIWRDESXULHD-UHFFFAOYSA-N Cc1c[n](cc[s]2)c2n1 Chemical compound Cc1c[n](cc[s]2)c2n1 VFPIWRDESXULHD-UHFFFAOYSA-N 0.000 description 1
- BZACBBRLMWHCNM-UHFFFAOYSA-N Cc1c[n](cccc2)c2n1 Chemical compound Cc1c[n](cccc2)c2n1 BZACBBRLMWHCNM-UHFFFAOYSA-N 0.000 description 1
- RSRQBWXGHCRSPD-UHFFFAOYSA-N Cc1c[n](cccn2)c2n1 Chemical compound Cc1c[n](cccn2)c2n1 RSRQBWXGHCRSPD-UHFFFAOYSA-N 0.000 description 1
- PUMREIFKTMLCAF-UHFFFAOYSA-N Cc1c[o]cn1 Chemical compound Cc1c[o]cn1 PUMREIFKTMLCAF-UHFFFAOYSA-N 0.000 description 1
- QMHIMXFNBOYPND-UHFFFAOYSA-N Cc1c[s]cn1 Chemical compound Cc1c[s]cn1 QMHIMXFNBOYPND-UHFFFAOYSA-N 0.000 description 1
- MXDRPNGTQDRKQM-UHFFFAOYSA-N Cc1cccnn1 Chemical compound Cc1cccnn1 MXDRPNGTQDRKQM-UHFFFAOYSA-N 0.000 description 1
- XKVUYEYANWFIJX-UHFFFAOYSA-N Cc1ccn[nH]1 Chemical compound Cc1ccn[nH]1 XKVUYEYANWFIJX-UHFFFAOYSA-N 0.000 description 1
- SMQAQNWCDKDKKO-UHFFFAOYSA-N Cc1n[n](cccn2)c2c1 Chemical compound Cc1n[n](cccn2)c2c1 SMQAQNWCDKDKKO-UHFFFAOYSA-N 0.000 description 1
- FICAQKBMCKEFDI-UHFFFAOYSA-N Cc1n[o]c(C)c1 Chemical compound Cc1n[o]c(C)c1 FICAQKBMCKEFDI-UHFFFAOYSA-N 0.000 description 1
- QLKJTZSQLHRFQI-UHFFFAOYSA-N Cc1n[o]c2c1COCC2 Chemical compound Cc1n[o]c2c1COCC2 QLKJTZSQLHRFQI-UHFFFAOYSA-N 0.000 description 1
- FZAXBPZVVJOFKX-UHFFFAOYSA-N Cc1n[o]cn1 Chemical compound Cc1n[o]cn1 FZAXBPZVVJOFKX-UHFFFAOYSA-N 0.000 description 1
- LDZYRENCLPUXAX-UHFFFAOYSA-N Cc1nc(cccc2)c2[nH]1 Chemical compound Cc1nc(cccc2)c2[nH]1 LDZYRENCLPUXAX-UHFFFAOYSA-N 0.000 description 1
- LXBGSDVWAMZHDD-UHFFFAOYSA-N Cc1ncc[nH]1 Chemical compound Cc1ncc[nH]1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 1
- VZWOXDYRBDIHMA-UHFFFAOYSA-N Cc1ncc[s]1 Chemical compound Cc1ncc[s]1 VZWOXDYRBDIHMA-UHFFFAOYSA-N 0.000 description 1
- RGTBLCLLSZPOKR-UHFFFAOYSA-N Cc1ncn[o]1 Chemical compound Cc1ncn[o]1 RGTBLCLLSZPOKR-UHFFFAOYSA-N 0.000 description 1
- ZMSIFDIKIXVLDF-UHFFFAOYSA-N Cc1nnc[o]1 Chemical compound Cc1nnc[o]1 ZMSIFDIKIXVLDF-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N c1ccncc1 Chemical compound c1ccncc1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N c1nc2cccnc2[nH]1 Chemical compound c1nc2cccnc2[nH]1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N c1nccnc1 Chemical compound c1nccnc1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25515909P | 2009-10-27 | 2009-10-27 | |
| US61/255,159 | 2009-10-27 | ||
| PCT/FI2010/000065 WO2011051540A1 (en) | 2009-10-27 | 2010-10-27 | Androgen receptor modulating compounds |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020127013214A Division KR101654529B1 (ko) | 2009-10-27 | 2010-10-27 | 안드로겐 수용체 조절 화합물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20160105927A KR20160105927A (ko) | 2016-09-07 |
| KR101670299B1 true KR101670299B1 (ko) | 2016-10-28 |
Family
ID=43383475
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167023703A KR101670299B1 (ko) | 2009-10-27 | 2010-10-27 | 안드로겐 수용체 조절 화합물 |
| KR1020127013214A KR101654529B1 (ko) | 2009-10-27 | 2010-10-27 | 안드로겐 수용체 조절 화합물 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020127013214A KR101654529B1 (ko) | 2009-10-27 | 2010-10-27 | 안드로겐 수용체 조절 화합물 |
Country Status (36)
| Country | Link |
|---|---|
| US (5) | US8975254B2 (en.) |
| EP (5) | EP3056485B1 (en.) |
| JP (1) | JP5763083B2 (en.) |
| KR (2) | KR101670299B1 (en.) |
| CN (2) | CN105061313B (en.) |
| AR (1) | AR078793A1 (en.) |
| AU (1) | AU2010311299C1 (en.) |
| BR (1) | BR112012008823B8 (en.) |
| CA (1) | CA2777896C (en.) |
| CL (1) | CL2012000772A1 (en.) |
| CO (1) | CO6531494A2 (en.) |
| CY (2) | CY2020010I2 (en.) |
| DK (3) | DK3056485T3 (en.) |
| EA (1) | EA021170B1 (en.) |
| ES (3) | ES2678073T3 (en.) |
| GE (1) | GEP20166472B (en.) |
| HK (1) | HK1173442A1 (en.) |
| HR (3) | HRP20140919T1 (en.) |
| HU (2) | HUE055528T2 (en.) |
| IL (2) | IL218586A (en.) |
| LT (3) | LT3369732T (en.) |
| LU (1) | LUC00154I2 (en.) |
| MX (1) | MX2012004867A (en.) |
| MY (1) | MY159924A (en.) |
| NL (1) | NL301041I2 (en.) |
| NO (1) | NO2020018I1 (en.) |
| NZ (1) | NZ598747A (en.) |
| PE (1) | PE20121058A1 (en.) |
| PL (3) | PL3056485T3 (en.) |
| PT (3) | PT3056485T (en.) |
| RS (3) | RS53469B (en.) |
| SI (3) | SI2493858T1 (en.) |
| SM (1) | SMT201400138B (en.) |
| UA (1) | UA109535C2 (en.) |
| WO (1) | WO2011051540A1 (en.) |
| ZA (1) | ZA201202655B (en.) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012007500A2 (de) * | 2010-07-15 | 2012-01-19 | Bayer Cropscience Ag | Neue heterocyclische verbindungen als schädlingsbekämpfungsmittel |
| EP2699561B1 (en) | 2011-04-21 | 2015-06-03 | Orion Corporation | Androgen receptor modulating carboxamides |
| EP2574607A1 (en) * | 2011-09-06 | 2013-04-03 | F. Hoffmann-La Roche AG | PDE10 modulators |
| AU2013202992B2 (en) * | 2012-03-15 | 2015-09-03 | Signal Pharmaceuticals, Llc | Treatment of cancer with TOR kinase inhibitors |
| TW201343644A (zh) * | 2012-03-23 | 2013-11-01 | Nihon Nohyaku Co Ltd | 噻唑羧醯胺衍生物及其使用方法 |
| SG11201408316SA (en) | 2012-06-15 | 2015-03-30 | Taisho Pharmaceutical Co Ltd | Branched chain alkyl heteroaromatic ring derivative |
| WO2014031784A1 (en) | 2012-08-23 | 2014-02-27 | Alios Biopharma, Inc. | Compounds for the treatment of paramoxyvirus viral infections |
| CN102952095A (zh) * | 2012-10-19 | 2013-03-06 | 盛世泰科生物医药技术(苏州)有限公司 | 一种2-羧酸乙酯-5-溴甲基噻唑的合成方法 |
| EA038819B1 (ru) * | 2013-08-21 | 2021-10-25 | Алиос Биофарма, Инк. | Противовирусные соединения |
| WO2015172196A1 (en) * | 2014-05-13 | 2015-11-19 | Monash University | Heterocyclic compounds and use of same |
| WO2016118666A1 (en) | 2015-01-20 | 2016-07-28 | Arvinas, Inc. | Compounds and methods for the targeted degradation of the androgen receptor |
| US20170327469A1 (en) | 2015-01-20 | 2017-11-16 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| SI3250554T1 (sl) | 2015-01-30 | 2022-09-30 | Orion Corporation | Derivat karboksiamida in njegovi diastereomeri v stabilni kristalinični obliki |
| MA41614A (fr) * | 2015-02-25 | 2018-01-02 | Alios Biopharma Inc | Composés antiviraux |
| SG11201707959VA (en) * | 2015-04-09 | 2017-10-30 | Orion Corp | Process for the preparation of androgen receptor antagonists and intermediates thereof |
| CA3024113A1 (en) * | 2015-05-18 | 2016-11-24 | Translational Drug Development, Llc | Heterocyclic compounds as kinase inhibitors |
| EP3388428B1 (en) * | 2015-12-07 | 2021-08-04 | Suzhou Sinovent Pharmaceuticals Company | Five-membered heterocyclic amides wnt pathway inhibitor |
| CN107286094A (zh) * | 2016-04-12 | 2017-10-24 | 常州爱诺新睿医药技术有限公司 | 一种bay-1841788与药用辅料的固体分散体及其制备方法 |
| LT3495352T (lt) * | 2016-08-26 | 2021-06-10 | Bayer Consumer Care Ag | Androgeno receptoriaus antagonisto kristalinės formos, paruošimo būdas ir jų panaudojimas |
| AU2017341723B2 (en) * | 2016-10-11 | 2021-12-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| EA201992103A1 (ru) | 2017-03-07 | 2020-01-24 | Орион Корпорейшн | Получение кристаллического фармацевтического продукта |
| US11185549B2 (en) | 2017-06-28 | 2021-11-30 | Bayer Consumer Care Ag | Combination of a PI3K-inhibitor with an androgen receptor antagonist |
| CN116396220A (zh) * | 2017-08-09 | 2023-07-07 | 杭州领业医药科技有限公司 | Odm-201晶型及其制备方法和药物组合物 |
| CN107602471B (zh) * | 2017-09-22 | 2021-04-27 | 成都恒汇化成医药科技有限公司 | 一种达罗鲁胺的晶型制备方法 |
| EP3759076A1 (en) | 2018-02-27 | 2021-01-06 | Sandoz AG | Crystalline form ii of darolutamide |
| JP2021535200A (ja) * | 2018-08-13 | 2021-12-16 | ナショナル・センター・フォー・バイオロジカル・サイエンス−ティーアイエフアール | 治療的介入のためのＨＩＶ−１ Ｎｅｆ−ＣＤ８０／ＣＤ８６相互作用を標的化する阻害剤 |
| US20210386826A1 (en) | 2018-11-05 | 2021-12-16 | Pfizer Inc. | Combination for Treating Cancer |
| AU2020215176A1 (en) | 2019-01-30 | 2021-08-05 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer |
| WO2020173457A1 (zh) * | 2019-02-27 | 2020-09-03 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡唑类化合物及包含该化合物的组合物及其用途 |
| EP3993779A1 (en) | 2019-07-02 | 2022-05-11 | Orion Corporation | Pharmaceutical composition of darolutamide |
| CN110590668A (zh) * | 2019-07-17 | 2019-12-20 | 江苏君若医药有限公司 | N-[(1s)-2-[3-(3-氯-4-氰基苯基)-1h-吡唑-1-基]-1-甲基乙基]-5-(1-羟基乙基)- 1h-吡唑-3-甲酰胺的制备方法 |
| AU2020327022A1 (en) | 2019-08-08 | 2022-02-10 | Laekna Limited | Method of treating cancer |
| CN111116476A (zh) * | 2019-12-27 | 2020-05-08 | 武汉九州钰民医药科技有限公司 | 制备抗肿瘤药物多拉米胺的方法 |
| JP2023528200A (ja) | 2020-05-11 | 2023-07-04 | オリオン コーポレーション | アンドロゲン受容体アンタゴニストおよびその中間体の製造方法 |
| BR112023002295A2 (pt) | 2020-08-13 | 2023-03-14 | Pfizer | Terapia de combinação |
| CN111978534B (zh) * | 2020-09-07 | 2022-05-31 | 陕西师范大学 | 一种含苯并咪唑液晶基元的侧链型液晶离聚物及其制备方法 |
| WO2022200982A1 (en) | 2021-03-24 | 2022-09-29 | Pfizer Inc. | Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer |
| CN113527208A (zh) * | 2021-08-31 | 2021-10-22 | 江西金丰药业有限公司 | 一步法制备2-氯-4-（1h-吡唑-3-基）苯甲腈的方法 |
| CN113861115A (zh) * | 2021-09-10 | 2021-12-31 | 浙江师范大学 | 一种吡唑酰胺类衍生物及合成方法和应用 |
| WO2023161458A1 (en) | 2022-02-28 | 2023-08-31 | Química Sintética, S.A. | Crystalline form of darolutamide |
| WO2023194528A1 (en) | 2022-04-07 | 2023-10-12 | Astrazeneca Ab | Combination therapy for treating cancer |
| WO2024074959A1 (en) | 2022-10-02 | 2024-04-11 | Pfizer Inc. | Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer |
| WO2024121163A1 (en) | 2022-12-06 | 2024-06-13 | Cancer Research Technology Limited | Combination of 10d1f and an androgen inhibitor for treatment and prevention of cancers |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007005887A2 (en) | 2005-07-01 | 2007-01-11 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds, compositions and uses thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU88769I2 (fr) | 1982-07-23 | 1996-11-05 | Zeneca Ltd | Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R)) |
| FR2656609B1 (fr) | 1989-12-28 | 1992-03-27 | Synthelabo | Derives de 2-aminopyrimidine-4-carboxamide, leur preparation et leur application en therapeutique. |
| US5578550A (en) | 1993-10-08 | 1996-11-26 | American Cyanamid Company | Herbicidal oxadiazole carbonamide compounds |
| FR2741342B1 (fr) | 1995-11-22 | 1998-02-06 | Roussel Uclaf | Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques |
| PL346795A1 (en) | 1998-09-22 | 2002-02-25 | Yamanouchi Pharma Co Ltd | Cyanophenyl derivatives |
| BR0213817A (pt) | 2001-11-02 | 2004-10-19 | Pfizer Prod Inc | Tratamento de sìndrome de resistência à insulina e diabete do tipo 2 com inibidores da pde9 |
| US20050119489A1 (en) * | 2001-12-28 | 2005-06-02 | Ladouceur Gaetan H. | 4-Sulfide/sulfoxide/sulfonyl-1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor |
| CA2471754A1 (en) | 2001-12-28 | 2003-07-17 | Takeda Chemical Industries, Ltd. | Androgen receptor antagonist |
| US20050119246A1 (en) * | 2001-12-28 | 2005-06-02 | Bayer Pharmaceuticals Corporation | 1H-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor |
| US20040180889A1 (en) | 2002-03-01 | 2004-09-16 | Pintex Pharmaceuticals, Inc. | Pin1-modulating compounds and methods of use thereof |
| AR040149A1 (es) * | 2002-06-07 | 2005-03-16 | Novartis Ag | Compuestos de aminoacetonitrilo, un proceso para su preparacion, composicion, y uso del compuesto |
| WO2004013130A1 (en) * | 2002-08-02 | 2004-02-12 | Argenta Discovery Limited | Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors |
| DE10322108B4 (de) | 2003-05-09 | 2008-12-11 | Bayer Schering Pharma Aktiengesellschaft | Antiandrogene Pyrrolidine mit tumorhemmender Wirksamkeit |
| WO2004111012A1 (ja) | 2003-06-12 | 2004-12-23 | Chugai Seiyaku Kabushiki Kaisha | イミダゾリジン誘導体 |
| JP4809228B2 (ja) | 2003-09-24 | 2011-11-09 | メチルジーン インコーポレイテッド | ヒストンデアセチラーゼの阻害剤 |
| WO2006028226A1 (ja) | 2004-09-09 | 2006-03-16 | Chugai Seiyaku Kabushiki Kaisha | 新規イミダゾリジン誘導体およびその用途 |
| JP2008007405A (ja) * | 2004-12-07 | 2008-01-17 | Takeda Chem Ind Ltd | カルボキサミド誘導体 |
| EP1710237A1 (en) * | 2005-04-08 | 2006-10-11 | Bayer CropScience S.A. | New heterocyclylethylbenzamide derivatives |
| NZ564223A (en) | 2005-05-13 | 2011-03-31 | Univ California | Diarylhydantoin compounds for treating hormone refractory prostate cancer |
| US7709516B2 (en) | 2005-06-17 | 2010-05-04 | Endorecherche, Inc. | Helix 12 directed non-steroidal antiandrogens |
| GB0518237D0 (en) * | 2005-09-07 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| CA2669736C (en) | 2005-11-03 | 2017-02-21 | Chembridge Research Laboratories, Inc. | Heterocyclic compounds as tyrosine kinase modulators |
| TW200800997A (en) | 2006-03-22 | 2008-01-01 | Astrazeneca Ab | Chemical compounds |
| JP5205274B2 (ja) | 2006-11-22 | 2013-06-05 | 日本農薬株式会社 | 新規なピラゾール誘導体、有害生物防除剤及びその使用方法 |
| WO2008124000A2 (en) | 2007-04-02 | 2008-10-16 | Ligand Pharmaceuticals Incorporated | Thiazole derivatives as androgen receptor modulator compounds |
| EP2167497A2 (en) | 2007-06-29 | 2010-03-31 | Sunesis Pharmaceuticals, Inc. | Heterocyclic compounds useful as raf kinase inhibitors |
| WO2009028543A1 (ja) | 2007-08-30 | 2009-03-05 | Takeda Pharmaceutical Company Limited | 置換ピラゾール誘導体 |
| JP5535925B2 (ja) | 2007-10-26 | 2014-07-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | アンドロゲン受容体調節物質としてのジアリールヒダントイン化合物 |
| UY31736A (es) | 2008-03-26 | 2009-11-10 | Takeda Pharmaceutical | Derivados sustituidos de pirazol y su uso |
| CA2725481A1 (en) * | 2008-06-18 | 2009-12-23 | Pfizer Limited | Nicotinamide derivatives |
-
2010
- 2010-10-26 AR ARP100103942A patent/AR078793A1/es active IP Right Grant
- 2010-10-27 PL PL16157716T patent/PL3056485T3/pl unknown
- 2010-10-27 RS RS20140420A patent/RS53469B/en unknown
- 2010-10-27 WO PCT/FI2010/000065 patent/WO2011051540A1/en active Application Filing
- 2010-10-27 LT LTEP18163765.3T patent/LT3369732T/lt unknown
- 2010-10-27 SI SI201030739T patent/SI2493858T1/sl unknown
- 2010-10-27 CN CN201510501603.4A patent/CN105061313B/zh active Active
- 2010-10-27 PT PT161577168T patent/PT3056485T/pt unknown
- 2010-10-27 EP EP16157716.8A patent/EP3056485B1/en active Active
- 2010-10-27 HU HUE18163765A patent/HUE055528T2/hu unknown
- 2010-10-27 DK DK16157716.8T patent/DK3056485T3/en active
- 2010-10-27 PT PT107819187T patent/PT2493858E/pt unknown
- 2010-10-27 CN CN201080048340.1A patent/CN102596910B/zh active Active
- 2010-10-27 HU HUE16157716A patent/HUE039390T2/hu unknown
- 2010-10-27 JP JP2012535889A patent/JP5763083B2/ja active Active
- 2010-10-27 PL PL18163765T patent/PL3369732T3/pl unknown
- 2010-10-27 SI SI201031718T patent/SI3056485T1/en unknown
- 2010-10-27 EP EP10781918.7A patent/EP2493858B1/en active Active
- 2010-10-27 DK DK18163765.3T patent/DK3369732T3/da active
- 2010-10-27 MY MYPI2012001441A patent/MY159924A/en unknown
- 2010-10-27 MX MX2012004867A patent/MX2012004867A/es active IP Right Grant
- 2010-10-27 NZ NZ598747A patent/NZ598747A/xx unknown
- 2010-10-27 EP EP18163765.3A patent/EP3369732B1/en active Active
- 2010-10-27 PT PT181637653T patent/PT3369732T/pt unknown
- 2010-10-27 EP EP14162075.7A patent/EP2754656A1/en not_active Withdrawn
- 2010-10-27 ES ES16157716.8T patent/ES2678073T3/es active Active
- 2010-10-27 EA EA201270597A patent/EA021170B1/ru active Protection Beyond IP Right Term
- 2010-10-27 BR BR112012008823A patent/BR112012008823B8/pt active IP Right Grant
- 2010-10-27 UA UAA201206302A patent/UA109535C2/ru unknown
- 2010-10-27 PE PE2012000424A patent/PE20121058A1/es active IP Right Grant
- 2010-10-27 RS RS20210903A patent/RS62123B1/sr unknown
- 2010-10-27 DK DK10781918.7T patent/DK2493858T3/da active
- 2010-10-27 ES ES10781918.7T patent/ES2486263T3/es active Active
- 2010-10-27 CA CA2777896A patent/CA2777896C/en active Active
- 2010-10-27 PL PL10781918T patent/PL2493858T3/pl unknown
- 2010-10-27 LT LTEP16157716.8T patent/LT3056485T/lt unknown
- 2010-10-27 AU AU2010311299A patent/AU2010311299C1/en active Active
- 2010-10-27 RS RS20180913A patent/RS57592B1/sr unknown
- 2010-10-27 GE GEAP201012722A patent/GEP20166472B/en unknown
- 2010-10-27 US US13/504,511 patent/US8975254B2/en active Active
- 2010-10-27 ES ES18163765T patent/ES2877248T3/es active Active
- 2010-10-27 KR KR1020167023703A patent/KR101670299B1/ko active IP Right Grant
- 2010-10-27 EP EP21169615.8A patent/EP3885340A1/en active Pending
- 2010-10-27 SI SI201032078T patent/SI3369732T1/sl unknown
- 2010-10-27 KR KR1020127013214A patent/KR101654529B1/ko active IP Right Grant
-
2012
- 2012-03-12 IL IL218586A patent/IL218586A/en active IP Right Grant
- 2012-03-28 CL CL2012000772A patent/CL2012000772A1/es unknown
- 2012-04-12 ZA ZA2012/02655A patent/ZA201202655B/en unknown
- 2012-04-27 CO CO12069611A patent/CO6531494A2/es active IP Right Grant
-
2013
- 2013-01-15 HK HK13100600.7A patent/HK1173442A1/zh unknown
-
2014
- 2014-09-23 SM SM201400138T patent/SMT201400138B/xx unknown
- 2014-09-26 HR HRP20140919AT patent/HRP20140919T1/hr unknown
-
2015
- 2015-01-16 US US14/598,973 patent/US9657003B2/en active Active
- 2015-03-30 IL IL238044A patent/IL238044A/en active IP Right Grant
-
2017
- 2017-04-13 US US15/486,995 patent/US10118933B2/en active Active
-
2018
- 2018-07-31 HR HRP20181229TT patent/HRP20181229T1/hr unknown
- 2018-09-25 US US16/140,716 patent/US10711013B2/en active Active
-
2020
- 2020-02-24 US US16/799,270 patent/US11046713B2/en active Active
- 2020-05-11 NL NL301041C patent/NL301041I2/nl unknown
- 2020-05-19 LU LU00154C patent/LUC00154I2/fr unknown
- 2020-06-05 CY CY2020010C patent/CY2020010I2/el unknown
- 2020-06-17 NO NO2020018C patent/NO2020018I1/no unknown
- 2020-06-26 LT LTPA2020514C patent/LTC2493858I2/lt unknown
-
2021
- 2021-07-22 HR HRP20211180TT patent/HRP20211180T1/hr unknown
- 2021-08-10 CY CY20211100717T patent/CY1124429T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007005887A2 (en) | 2005-07-01 | 2007-01-11 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds, compositions and uses thereof |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101670299B1 (ko) | 안드로겐 수용체 조절 화합물 | |
| CN108329246B (zh) | 作为trka激酶抑制剂的吡咯烷基脲和吡咯烷基硫脲化合物 | |
| JP6967112B2 (ja) | 新規なフェロポーチン阻害剤 | |
| KR101958177B1 (ko) | 안드로겐 수용체 조절성 카복스아미드 | |
| AU2009279089B2 (en) | Cyclohexyl amide derivatives and their use as CRF-1 receptor antagonists | |
| KR101077366B1 (ko) | 11-베타-ｈｓｄ-1로서의 피라졸 | |
| KR100569324B1 (ko) | Ｈｉｖ 치료용 피라졸 유도체 | |
| CA2958490A1 (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | |
| EP1835934A2 (en) | Enzyme modulators and treatments | |
| AU2002242926A1 (en) | Pyrazole derivatives for treating HIV | |
| CN101111483A (zh) | Igf-1r抑制剂 | |
| CN1980912A (zh) | 吡唑衍生物 | |
| WO2023154519A1 (en) | Inhibitors of rna helicase dhx9 and uses thereof | |
| CN101679447A (zh) | 嘧啶并二氮杂酮衍生物 | |
| TWI636047B (zh) | 雜環衍生物 | |
| EA039916B1 (ru) | Новые ингибиторы ферропортина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| A201 | Request for examination | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |